First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 805.7 INR -1.14% Market Closed
Updated: Apr 29, 2024

Glenmark Life Sciences Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Life Sciences Ltd
Cash from Operating Activities Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
M
MANKIND

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Cash from Operating Activities
₹3.1B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Operating Activities
₹72.1B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Operating Activities
₹37.9B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Operating Activities
₹121.9B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash from Operating Activities
₹37.7B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash from Operating Activities
₹18.1B
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Glenmark Life Sciences Ltd's Cash from Operating Activities?
Cash from Operating Activities
3.1B INR

Based on the financial report for Mar 31, 2023, Glenmark Life Sciences Ltd's Cash from Operating Activities amounts to 3.1B INR.

What is Glenmark Life Sciences Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
17%

Over the last year, the Cash from Operating Activities growth was -48%. The average annual Cash from Operating Activities growth rates for Glenmark Life Sciences Ltd have been 17% over the past three years .